Group | Clinical TB Research

Despite progress in the fight against tuberculosis (TB), TB remains a major global health problem. Innovative, high-quality research is needed to combat this poverty-related disease, which primarily affects the most vulnerable.

The mission of our Clinical TB Research Group is to improve the prevention, diagnosis and treatment of TB and its comorbidities especially in high-burden countries. Our portfolio includes clinical trials, intervention studies, translational research and epidemiological studies.

Lines of research

The focus of our research activities is on the following areas:

  • Community-based active case finding strategies for TB
  • Clinical evaluation of new tools against TB with emphasis on diagnostics and biomarkers
  • Host-directed therapies for TB
  • Molecular epidemiology
  • TB comorbidities




TB Triage+ Community-based tuberculosis triage testing for hard-to-reach populations in Southern Africa

Tuberculosis is a poverty-related disease which particularly affects vulnerable and underserved populations. WHO has developed target product profiles for community-based TB triage testing. CAD4TB, an extensively validated digital chest x-ray analysis platform using deep-learning technology, and a blood test for C-reactive protein, which is a marker of inflammation or infection, are two very promising diagnostic tools which have the potential to meet the targets for TB triage. Read more

MistraL - Mitigation strategies for communities with COVID-19 transmission in Lesotho using artificial intelligence on chest x-rays and novel rapid diagnostic tests

For mitigation strategies to be effective and efficient against COVID-19, they must be context-specific and take local conditions into account. In low- and lower-middle-income countries, limited resources and fragile healthcare systems often dictate what is feasible. In this project, researchers combine artificial intelligence, portable chest X-ray machines and antigen-based diagnostic tests to enable and improve diagnosis of COVID-19 patients in settings with limited resources. Read more

TB-CAPT - Facilitating implementation of TB testing

TB-CAPT (Close the gap, increase Access, Provide adequate Therapy) will provide evidence for impactful implementation of tuberculosis (TB) and TB/HIV co-infection diagnostic strategies including drug-susceptibility testing through a series of trials in Tanzania, Mozambique, and South Africa. TB-CAPT is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and will run for 3.5 years, with planned completion in 2023. Read more

Hetzel M.W et al. Pre-referral rectal artesunate is no "magic bullet" in weak health systems. BMC Med. 2023;21:119. DOI: 10.1186/s12916-023-02777-y

Keter A.K et al. Evaluation of tuberculosis diagnostic test accuracy using Bayesian latent class analysis in the presence of conditional dependence between the diagnostic tests used in a community-based tuberculosis screening study. PLoS One. 2023;18(3):e0282417. DOI: 10.1371/journal.pone.0282417

Labhardt N.D et al. Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid antigen testing in Lesotho. PLoS One. 2023;18(3):e0278653. DOI: 10.1371/journal.pone.0278653

Lambiris M.J et al. Health system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints. Lancet Glob Health. 2023;11(2):e256-e264. DOI: 10.1016/S2214-109X(22)00507-1

Loiseau C et al. The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot. Nat Commun. 2023;14:1988. DOI: 10.1038/s41467-023-37719-y